Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
-
- Miyawaki Hiroshi
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan
-
- Kioka Hidetaka
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan
-
- Sato Kazuaki
- Department of Pathology, Osaka University Graduate School of Medicine, Japan
-
- Kurashige Masako
- Department of Pathology, Osaka University Graduate School of Medicine, Japan
-
- Ozawa Takayuki
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan
-
- Shibayama Hirohiko
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan
-
- Hikoso Shungo
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan
-
- Morii Eiichi
- Department of Pathology, Osaka University Graduate School of Medicine, Japan
-
- Yamauchi-Takihara Keiko
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan Health Care Center, Osaka University, Japan
-
- Sakata Yasushi
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan
Search this article
Description
<p>Constitutive activation of the Janus kinase/signal transduction and activator of transcription (JAK-STAT) signaling pathway plays a central role in the pathogenesis of myelofibrosis (MF) and pulmonary hypertension (PH) is a known complication of MF. On the other hand, it has been proposed that the JAK-STAT pathway, especially signal transducer and activation of transcription (STAT) 3 activation, protects cardiomyocytes from various stresses. We describe the case of a patient with MF-associated PH who developed left ventricular dysfunction after five years of treatment with the JAK 1/2 inhibitor, ruxolitinib. This is the first report with histopathological findings that demonstrate possible contradictory effects of a JAK 1/2 inhibitor: improvement of MF-associated PH and cardiotoxicity. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 59 (2), 229-233, 2020-01-15
The Japanese Society of Internal Medicine
